PTC Therapeutics Inc (NASDAQ: PTCT) closed the day trading at $25.68 down -2.80% from the previous closing price of $26.42. On the day, 962566 shares were traded.
Ratios:
For a better understanding of PTCT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.97 and its Current Ratio is at 2.02.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $37.
Oppenheimer Upgraded its Perform to Outperform on October 30, 2023, while the target price for the stock was maintained at $165.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 02 ’24 when Golden Lee Scott sold 526 shares for $28.37 per share. The transaction valued at 14,923 led to the insider holds 59,988 shares of the business.
Boulding Mark Elliott sold 794 shares of PTCT for $21,637 on Jan 30 ’24. The EXEC. VP AND CLO now owns 71,189 shares after completing the transaction at $27.25 per share. On Jan 30 ’24, another insider, Almstead Neil Gregory, who serves as the CHIEF TECHNICAL OPS OFFICER of the company, sold 618 shares for $27.25 each. As a result, the insider received 16,841 and left with 61,202 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.10.
Stock Price History:
Over the past 52 weeks, PTCT has reached a high of $59.84, while it has fallen to a 52-week low of $17.53.
Shares Statistics:
A total of 75.71M shares are outstanding, with a floating share count of 73.71M. Insiders hold about 3.79% of the company’s shares, while institutions hold 110.35% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 13 analysts. On average, analysts expect EPS of -$1.25 for the current quarter, with a high estimate of -$0.56 and a low estimate of -$1.93, while EPS last year was -$1.88. The consensus estimate for the next quarter is -$1.54, with high estimates of -$1.06 and low estimates of -$2.66.
Analysts are recommending an EPS of between -$2.66 and -$8.45 for the fiscal current year, implying an average EPS of -$5.87. EPS for the following year is -$4.96, with 14 analysts recommending between -$1.95 and -$9.16.
Revenue Estimates
10 analysts predict $170.43M in revenue for the current quarter. It ranges from a high estimate of $209.6M to a low estimate of $143.5M. As of the current estimate, PTC Therapeutics Inc’s year-ago sales were $220.38M, an estimated decrease of -22.70% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $149.08M, a decrease of -30.30% less than the figure of -$22.70% in the same quarter last year. There is a high estimate of $169.37M for the next quarter, whereas the lowest estimate is $136.5M.
A total of 13 analysts have provided revenue estimates for PTCT’s current fiscal year. The highest revenue estimate was $675.8M, while the lowest revenue estimate was $469.7M, resulting in an average revenue estimate of $607.16M. In the same quarter a year ago, actual revenue was $937.82M, down -35.30% from the average estimate. Based on 13 analysts’ estimates, the company’s revenue will be $624.52M in the next fiscal year. The high estimate is $757.29M and the low estimate is $332.8M. The average revenue growth estimate for next year is up 2.90% from the average revenue estimate for this year.
